POLYTECH is founded in Dieburg, near Frankfurt am Main. The company initially focuses on the distribution of medical devices for conservative orthopaedic treatment and compression garments for burn patients.
The US medical device manufacturer Cooper Surgical and its affiliates Aesthetec and Natural Y commission POLYTECH to investigate by means of a qualitative and quantitative market assessment whether it would be worth expanding into the German market for breast implants.
POLYTECH starts to distribute breast implants in Germany.
POLYTECH expands its product portfolio: In addition to breast implants, it now includes calf implants and buttock implants. At this time, they are still manufactured in Brazil.
POLYTECH introduces the implant passport.
In collaboration with doctors and surgeons, POLYTECH advances the development of polyurethane foam-covered silicone implants.
The production facility in Dieburg is expanded and clean rooms are set up for quality controls, packaging and sterilisation of the implants.
POLYTECH extends its cooperation with distribution partners, thereby expanding its distribution network throughout Europe.
Broadening of marketing and distribution operations.
Since 1995, POLYTECH products have been allowed to bear the CE mark.
In 2003, POLYTECH is the first company in the world to receive approval for Class III certification for breast implants.
All production operations are relocated to Dieburg. Marketing and distribution operations are expanded and targeted at the international market.
The company changes its name to POLYTECH Health & Aesthetics.
A distribution network is established in the Asia-Pacific Region with a focus on Australia, New Zealand, Vietnam and Malaysia.
POLYTECH celebrates its 25th anniversary.
The distribution structures in Central and South America are expanded and consolidated, and market entry into China is being prepared.
The existing production facilities are modernised and preparations are being made for a sustainable expansion of capacity.
Production capacity is increased by 50%.
POLYTECH increases its distribution network in the EMEA and in Central America.
POLYTECH strengthens its international distribution team and fills two management posts for South America and Asia. At the same time, the German sales and customer service team are expanded.
Product authorisation in China is being prepared.
POLYTECH extends the Dieburg production site by 800 square metres.
30 new employees are hired at the company headquarters in Dieburg and the increase in the areas of production, approval and quality management is initiated.
A new CEO takes over the leadership of POLYTECH.
POLYTECH receives approval for the sale of breast implants in China.
The expansion of the distribution network in Asia is being prepared; the focus is on Taiwan, Indonesia, Thailand and Malaysia.
To promote the growth of the company, Deutsche Beteiligungs AG (DBAG) acquires a majority stake in POLYTECH as part of a management buyout. The new company owners set the course for future growth and profitability.
The publication of the first long-term study on the tolerability of polyurethane breast implants in primary augmentation is initiated.
The expansion of the production facilities in Dieburg is completed and operations are started in the new clean rooms.
A clinical study on an innovative silk protein coating for implant surfaces, which was developed together with the company AMSilk, is being prepared.
A long-term study of the tolerability of polyurethane implants in breast reconstruction is published, followed by a study on the compatibility of our implants in breast augmentation.